Skip to main content
SpringerLink
Log in
Book cover

Symposium in Immunology I and II pp 255–262Cite as

Intravenous Immunoglobulins in the Treatment of Autoimmune Diseases

  • Conference paper

  • 28 Accesses

Abstract

Intravenous immunoglobulins (IVIg) have been used increasingly over the past 10 years in the treatment of a large number of autoimmune and systemic inflammatory diseases [1]. A recent consensus conference conducted by the National Institute of Health [2] has emphasized the need for a better understanding of the mechanisms by which IVIg modulate autoimmune responses. As discussed in this review, the immunomodulatory effects of IVIg may depend on interactions between the Fc portion of infused IgG with Fc receptors on inflammatory cells and lymphocytes and/or on the modulation of the expressed antibody repertoire through the interaction of variable regions of IVIg with circulating immunoglobulins and antigen receptors on immunocompetent cells.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD (1991) Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol 86: 192–198

    Article  PubMed  CAS  Google Scholar 

  2. Department of Health and Human Services (1990) Intravenous immune globulin: consensus statement. NIH Consensus Developement Conference May 1990, vol 8 (5). Department of Health and Human Services, Bethesda, pp 21–23

    Google Scholar 

  3. Dwyer MD (1992) Manipulating the immune system with immune globulin. N Engl J Med 326: 107–116

    Article  PubMed  CAS  Google Scholar 

  4. Imbach P, Muller B, Imholz B et al. (1986) Intravenous immunoglobulin therapy in immune thrombocytopenic purpura (ITP) and other immune related haemorrhagic disorders in childhood. In: Morell A, Nydegger UE (eds) Clinical use of intravenous immunoglobulins. Academic, London, pp 177–186

    Google Scholar 

  5. Fehr J, Hofmann V, Kappeier U (1982) Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high dose intravenous gammaglobulin. N Engl J Med 306: 1254–1258

    Article  PubMed  CAS  Google Scholar 

  6. Berchtold P, Dale GL,Tani P et al. (1989) Inhibition of autoantibody binding to platelet glycoprotein IIb/IIa by anti-idiotypic antibodies in intravenous immunoglobulins. Blood 74: 2414–2417

    PubMed  CAS  Google Scholar 

  7. Sultan Y, Kazatchkine MD, Maisonneuve P et al. (1984) Anti-idiotypic suppression of autoantibodies to factor VIII (anti-haemophilic factor) by high-dose intravenous immunoglobulin. Lancet ii: 765–768

    Google Scholar 

  8. Sultan Y, Rossi F, Kazatchkine MD (1987) Recovery from anti-VIIIc (anti-hemophilic factor) autoimmune disease is dependent on generation of anti-idiotypes against anti-VIIIc autoantibodies. Proc Natl Acad Sci USA 84: 828–831

    Article  PubMed  CAS  Google Scholar 

  9. Jayne DRW, Davies MJ, Fox CJV et al. (1991) Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337: 1137–1139

    Article  PubMed  CAS  Google Scholar 

  10. Rossi F, Jayne DRW, Lockwood CM et al. (1991) Anti-idiotypes against anti-neutrophil cytoplasm antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 83: 1–6

    Google Scholar 

  11. Kimberly RP, Salmon JE, Bussel JB et al. (1984) Modulation of mononuclear phagocyte function by intravenous gammaglobulin. J Immunol 132: 745–750

    PubMed  CAS  Google Scholar 

  12. Salama A, Mueller-Eckhart C, Kiefel V (1983) Effect of intravenous immunoglobulin in immune thrombocytopenia. Competitive inhibition of the reticuloendothelial system function by sequestration by autologous red blood cells. Lancet ii: 193–195

    Google Scholar 

  13. Clarkson SB, Bussel JB, Kimberly RP et al. (1986) Treatment of refractory immune thrombocytopenic purpura with an anti Fc gamma receptor antibody. N Engl J Med 314: 1236–1239

    Article  PubMed  CAS  Google Scholar 

  14. Uher F, Dickler HB (1986) Cooperativity between B lymphocyte membrane molecules: independent ligand occupancy and cross-linking of antigen receptors and Fey receptors down regulates B lymphocyte function. J Immunol 137: 3124–3129

    PubMed  CAS  Google Scholar 

  15. Shimozato T, Iwata M, Kawada H et al. (1991) Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′:5′-monophosphate levels, resulting in suppression of tumor necrosis factor alpha and interleukin-1 production. Immunology 72: 497–501

    PubMed  CAS  Google Scholar 

  16. Iwata M, Shimozato T, Tokiwa H, Tsubura E (1987) Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits. Infect Immun 55: 547–552

    PubMed  CAS  Google Scholar 

  17. Basta M, Langlois PF, Marques M et al. (1989) High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 74: 326–333

    PubMed  CAS  Google Scholar 

  18. Van Doom PA, Rossi F, Brand A et al. (1990) On the mechanism of high dose intravenous immunoglobulin treatment of patients with chronic inflammatory demye-linating polyneuropathy. J Neuroimmunology 29: 57–64

    Article  Google Scholar 

  19. McGuire WA, Yang HH, Bruno E et al. (1987) Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gammaglobulin. N Engl J Med 317: 1004–1008

    Article  PubMed  CAS  Google Scholar 

  20. Rossi F, Sultan Y, Kazatchkine MD (1988) Anti-idiotypes against autoantibodies and alloantibodies to factor VIIIc (anti-hemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 74: 311–316

    PubMed  CAS  Google Scholar 

  21. Rossi F, Kazatchkine MD (1989) Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 143: 4104–4109

    PubMed  CAS  Google Scholar 

  22. Dietrich G, Kazatchkine MD (1990) Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specifities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 85: 620–625

    Article  PubMed  CAS  Google Scholar 

  23. Dietrich G, Algiman M, Sultan Y et al. (1992) Origin of anti-idiotypic activity against autoantibody in pools of normal human immunoglobulin G (IVIg). Blood 79: 1–5

    Google Scholar 

  24. Roux KH, Tankersley DL (1990) A view of the human idiotypic repertoire: electron microscopic and immunologic analysis of spontaneous idiotype — anti-idiotype dimers in pooled human IgG. J Immunol 144: 1387–1395

    PubMed  CAS  Google Scholar 

  25. Rossi F, Guilbert B, Tonnelle C et al. (1990) Idiotypic interactions between normal human polyspecific IgG and natural IgM antibodies. Eur J Immunol 20: 2089–2094

    Article  PubMed  CAS  Google Scholar 

  26. Dietrich G, Kaveri SV, Kazatchkine MD (1992) A V region-connected subfraction of normal human serum immunoglobulin G. Eur J Immunol 22: 1701–1706

    Article  PubMed  CAS  Google Scholar 

  27. Varela F, Anderson A, Dietrich G et al. (1991) The population dynamics of antibodies in normal and autoimmune individuals. Proc Natl Acad Sci USA 88: 5917–5921

    Article  PubMed  CAS  Google Scholar 

  28. Freitas AA, Viale AC, Sundblad A et al. (1991) Normal serum immunoglobulins participate in the selection of peripheral B-cell repertoires. Proc Natl Acad Sci USA 88: 5640–5644

    Article  PubMed  CAS  Google Scholar 

  29. Dietrich G, Kaveri SV, Kazatchkine MD (1992) Modulation of autoimmunity by intravenous immunoglobulins (IVIg) through interactions with the function of the immune/idiotypic network. Clin Immunol Immunopathol 62: S73–S81

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. V. Hurez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. D. Kazatchkine
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Immunologie der Universität Wien, Borschkegasse 8 a, 1090, Wien, Austria

    Martha M. Eibl

  2. Abteilung für Hämatologie, Johannes Gutenberg Universität, Langenbeckstr. 1, 6500, Mainz, Germany

    Christoph Huber

  3. Abteilung für Rheumatologie und Klinische Immunologie, Medizinische Universitätsklinik, Hugstetter Str. 55, 7800, Freiburg i.Br., Germany

    Hans H. Peter

  4. Päd. Pneumologie und Immunologie, Univ.-Klinikum Rudolf Virchow, Standort Charlottenburg, Heubnerweg 6, 1000, Berlin 19, Germany

    Ulrich Wahn

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Hurez, V., Kazatchkine, M.D. (1993). Intravenous Immunoglobulins in the Treatment of Autoimmune Diseases. In: Eibl, M.M., Huber, C., Peter, H.H., Wahn, U. (eds) Symposium in Immunology I and II. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78087-5_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78087-5_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-56478-2

  • Online ISBN: 978-3-642-78087-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation